Composition for activating PGC-1α
A composition of natural compounds activates PGC-1α, addressing the lack of alternatives to resveratrol by enhancing endurance, muscle growth, obesity control, and metabolic functions, benefiting individuals with chronic conditions.
Patent Information
- Application Number
- JP2024134823
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-10-27
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2037-10-27
AI Technical Summary
There is a need for compounds that can safely activate PGC-1α, as resveratrol is the only known natural compound with this effect, and there is a demand for rapid development of such substances.
A composition comprising various compounds derived from natural products, including chalcones, alkaloids, anthraquinones, isoflavones, ellagic acid, coumarins, diallylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, and lignans, is developed to activate PGC-1α.
The composition effectively activates PGC-1α, leading to improved endurance, muscle hypertrophy, obesity suppression, stress reduction, and enhanced glucose metabolic function, contributing to better quality of life for individuals with chronic illnesses and the elderly.
Smart Images

Figure 2024160348000001 
Figure 2024160348000002 
Figure 2024160348000003
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions useful for activating PGC-1α that contain certain compounds. [Background technology]
[0002] Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is known as a factor that controls energy metabolism in the body. PGC-1α was initially identified as a transcriptional coactivator that activates transcription by the nuclear receptor PPARγ in brown adipose tissue. It has since been revealed that PGC-1α interacts with not only PPARγ but also many other nuclear receptors and various transcription factors, and controls the expression of target genes as a transcriptional coactivator.
[0003] PGC-1α expression is increased in skeletal muscle by exercise, and is involved in the increased expression of genes related to mitochondrial biosynthesis and energy metabolism. It is also known that PGC-1α plays a role in controlling cellular energy production by promoting mitochondrial biosynthesis and oxidative phosphorylation in organs such as fat, brain, and blood vessels. Based on this control of energy production, the functions of PGC-1α are known to be involved in improving endurance (Non-Patent Document 1), muscle hypertrophy (Non-Patent Document 2), suppressing obesity (Non-Patent Document 3), reducing stress (Non-Patent Document 4), improving glucose metabolism function (Non-Patent Document 5), and suppressing muscle atrophy (Non-Patent Document 6).
[0004] When the body is in a state of energy deficiency, the intracellular AMP concentration increases, activating AMPK (AMP kinase). This AMPK promotes the phosphorylation of PGC-1α and promotes the deacetylation of PGC-1α. As a result, PGC-1α localized in the cytoplasm migrates into the cell nucleus and promotes the expression of target genes as a transcriptional coactivator (Non-Patent Document 7).
[0005] Among compounds derived from natural products, it has been reported that resveratrol contained in wine activates AMPK through inhibition of phosphodiesterase, thereby activating PGC-1α (Non-Patent Document 8), but there have been no reports on the ability of other natural product components to activate PGC-1α. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Nature. 2008 Jul 24;454(7203):463-9. [Non-Patent Document 2] Cell. 2012 Dec 7;151(6):1319-31. [Non-Patent Document 3] Nature. 2012 Jan 11;481(7382):463-8. [Non-Patent Document 4] Cell. 2014 Sep 25;159(1):33-45. [Non-Patent Document 5] J Biol Chem. 2003 Aug 15;278(33):31385-90. [Non-Patent Document 6] Proc Natl Acad Sci USA 2009; 106: 20405-20410 [Non-Patent Document 7] Diabetes, 2007 Jan 19;56(3): 836-48. [Non-Patent Document 8] Cell. 2012 Feb 3;148(3): 421-33. Summary of the Invention [Problem to be solved by the invention]
[0007] Compounds that activate PGC-1α are expected to exert the above-mentioned effects, such as improving endurance and muscle hypertrophy. However, so far, there have been no compounds with such effects that are easy to obtain and have a high level of safety as natural products that can be widely used in the food and beverage industry. No other substance has been found to have such properties other than resveratrol, and there is a strong demand for its rapid development.
[0008] Therefore, an object of the present invention is to provide a composition that is highly biologically safe and contributes to the activation of PGC-1α. Another object of the present invention is to provide a use of the composition for activating PGC-1α, and a method for activating PGC-1α. [Means for solving the problem]
[0009] As a result of intensive research conducted by the present inventors to achieve the above object, they have found that certain compounds derived from natural products have an activating effect on PGC-1α. Based on this finding, the present inventors have completed the present invention.
[0010] That is, the present invention relates to, but is not limited to, the following: (1) A composition for activating PGC-1α, comprising at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans. (2) Chalcones include 2-hydroxychalcone, trans-chalcone, isoliquiritigenin, 4'-hydroxychalcone, 2',4'-dihydroxy-4,6'-dimethoxychalcone, and 4-hydroxy Chalcone, 4'-methoxychalcone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 2',6'-dihydroxy-4,4'-dimethoxydihydrochalcone, 2',6'-dihydroxy-4,4'-dimethoxy Toxichalcone, 4-methoxychalcone, and 3,4,2',4',6'-pentahydroxychalcone The composition according to (1), wherein the compound is at least one compound selected from the group consisting of: (3) The composition according to (1) or (2), wherein the alkaloids are piperlongumine and / or mahanine. (4) The composition according to any one of (1) to (3), wherein the anthraquinone is emodin and / or anthraflavic acid. (5) The composition according to any one of (1) to (4), wherein the isoflavan is (±)-equol. composition. (6) Isoflavones are 4',6,7-trihydroxyisoflavone, 5-methyl-7-methoxy- The composition according to any one of (1) to (5), which is at least one compound selected from the group consisting of isoflavone and ipriflavone. (7) The composition according to any one of (1) to (6), wherein the ellagic acid is urolithin and / or ellagic acid. (8) The composition according to any one of (1) to (7), wherein the coumarin is esculetin, (9) The composition according to any one of (1) to (8), wherein the diarylheptanoid is at least one compound selected from the group consisting of curcumin 1, curcumin 2, and curcumin 3. (10) The composition according to any one of (1) to (9), wherein the diterpenoid is isosteviol. (11) The sesquiterpenes are (-)-trans caryophyllene and / or nootkatone. The composition according to any one of (1) to (10). (12) The composition according to any one of (1) to (11), wherein the triterpenes are hederagenin and / or corosolic acid. (13) The composition according to any one of (1) to (12), wherein the neoflavones are dalbergines. (14) The composition according to any one of (1) to (13), wherein the phytochemical is at least one compound selected from the group consisting of apocynin, 3-anisaldehyde, (+)-cuparene, and hydroxytyrosol. (15) The composition according to any one of (1) to (14), wherein the flavanonol is (+)-taxifolin. (16) Flavanones are 4'-methoxyflavanone, 2'-hydroxyflavanone, 3'-hydroxy The composition according to any one of (1) to (15), wherein the at least one compound is selected from the group consisting of roxyflavanone, flavanone, and 6-methoxyflavanone. (17) Flavonols include galangin, 3-methoxyflavone, kaempferol, and 3',5,7- Trihydroxy-3,4'-dimethoxyflavone, 3',4',5,5',6,7,8-heptamethoxyflavone The composition according to any one of (1) to (16), wherein the compound is at least one compound selected from the group consisting of fisetin, 6-methoxyflavonol, 7-hydroxyflavonol, and isorhamnetin. (18) The flavones are at least one selected from the group consisting of biolanthin, 3',4'-dihydroxyflavone, tangeretin, 2'-methoxyflavone, 7,4'-dihydroxyflavone, chrysoeriol, 3',4'-dimethoxyflavone, flavone, α-naphthoflavone, diosmetin, 4'-methoxyflavone, wogonin, 6-hydroxyflavone, and 5-methoxyflavone. The composition according to any one of (1) to (17), which is at least one compound. (19) The composition according to any one of (1) to (18), wherein the lignans are at least one compound selected from the group consisting of eudesmin, (-)-sesamin, honokiol, sesamolin, sesamin, nordihydroguaiaretic acid, sesaminol, sesamol, episesamin, and matairesinol. (20) The composition according to any one of (1) to (19), which is for improving endurance, for increasing muscle hypertrophy, for suppressing obesity, for reducing stress, for improving glucose metabolic function, or for suppressing muscle atrophy. (21) The composition according to any one of (1) to (20), which is labeled with a function exerted by activation of PGC-1α. (22) The composition according to (21), wherein the function indication is selected from the group consisting of “enhance endurance”, “support endurance”, “maintain endurance”, “build endurance”, “help to increase stamina”, “make the body less prone to fatigue”, “reduce fatigue”, “suppress fatigue”, “speed up recovery from fatigue”, “build muscle”, “increase muscle”, “build muscle”, “reduce fat”, “burn fat”, “suppress obesity”, “prevent obesity”, “enhance lipid metabolism”, “reduce stress”, “enhance stress tolerance”, “suppress depression”, “prevent depression”, “promote glucose metabolism”, “enhance glucose metabolism”, “promote sugar burning”, “support glucose metabolism”, “consume sugar”, “maintain muscle”, “suppress muscle atrophy”, “prevent muscle loss”, “suppress muscle loss”, “prevent muscle decline”, and “suppress muscle decline”. (23) Use of at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans, for activating PGC-1α. (24) A method for activating PGC-1α using at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans. Effect of the Invention
[0011] The present invention provides a composition having excellent PGC-1α activation activity. By using the composition of the present invention, the effects of improving endurance, muscle hypertrophy, suppressing obesity, reducing stress, improving glucose metabolism function, and suppressing muscle atrophy can be obtained through the activation of PGC-1α. The achievement of these effects by the present invention leads to the provision of a new means for improving the QOL of patients and the elderly.
[0012] In addition, since all of the specific compounds used in the present invention are derived from natural products, they are considered to be highly safe. Therefore, the present invention can provide a composition that has excellent PGC-1α activating activity and is safe and can be taken continuously. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] (compound) One aspect of the present invention is a composition containing a specific compound. The composition of the present invention contains the specific compound as an active ingredient.
[0014] In the composition of the present invention, chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and At least one compound selected from the group consisting of lignans is included. The composition of the present invention may contain two or more of the above compounds, or may contain three or more of the above compounds.
[0015] The compounds used in the present invention include trans-chalcone, 2',4'-dihydroxy-4,6'-dimethoxychalcone, 2',6'-dihydroxy-4,4'-dimethoxychalcone, 2-hydroxychalcone, 3,4,2',4',6'-pentahydroxychalcon, acacetin, acteoside, andrographolide, apigenin, apigeninidine chloride, and the like. chloride), Baicalein, Baicalin, Butein, Chrysin, Cyanin, Dye Zein, Delphin, Delphinidin Chloride, δ-(3,4-Dihydroxyphenyl)-γ-valerolactone, Diosmetin, Diosmin, Ellipse Ellagic acid, Eriodictyol, Fisetin, Flavone, Galangin, Gallic acid, Sanguisorbic acid, Hesperetin, Isoliquiritigenin, Kaempferol, Lipoic acid, Luteol Luteolin, Mahanine, Myricetin, Protocatechuic acid, Procyanidin B2, Quercetin dihydrate, Sesamin, Episesamin, Tellimagrandin 1, Tellimagrandin 2, Theobromine, Theophylline, Wogonin, Silibinin, Rottlerin, 6-Hydroxyflavone, 7-Hydroxyflavone, Isorhamnetin, Morin, Biochanin A A), Chrysoeriol, Formononetin, Peonidin Chloride, Ame Amentoflavone, Cupressuflavone, 3',4'-Dihydroxyflavone, 7,4'-Dihydroxyflavone, 7,8-Dihydroxyflavone, 6,7-Dihydroxyflavone, 3',4'-Dimethoxyflavone, 3-Hydroxyflavone, Ipriflavone, 2 '-Methoxyflavone, 3-Methoxyflavone , 5-Methoxyflavone, 4'-Methoxyflavone, 5-Methyl-7-methoxy-isoflavone, 3',4',5',5,7-Pentamethoxyflavone, 3',4',7,8-Tetrahydroxyflavone 3',5,7-trihydroxy-3,4'-dimethoxyflavone, 4',6,7-trihydroxyisoflavone, 7-hydroxyflavonol, 7-methoxyflavonol, 6-methoxyflavonol 6-Methoxyflavonol, Flavanone, Flavanone hydrazone, 2'-Hydroxyflavanone, 4'-Hydroxyflavanone, 3'-Hydroxyflavanone , α-Naphthoflavone, 4'-Methoxyflavanone, 5-Methoxyflavanone, 6-Methoxyflavanone, 2',6'-Dihydroxy-4,4'-dimethoxydihydrochalcone, 2',6'-Dihydroxy-4'-methoxychalcone ihydroxy-4'-methoxychalcone, 2,3-dimethoxy-2'-hydroxychalcone, sesaminol, 4-methoxychalcone, 4'-methoxychalcone, quercetin-3,7,3',4'-tetramethylether, fisetinidin Chloride (Fisetinidin chloride), Luteolinidin chloride ), 8-Acetyl-6-hydroxy-7-methoxycoumarin, 8-Acetyl-7-methoxycoumarin, 3-amino 3-Aminocoumarin, Bergamotin, Bergapten, Bergaptol, Citropten, Coumarin, Coumaric acid, Coumestrol, Dalbergin, Daphnetin, 5,7-Dihydroxy-4-methylcoumarin, Esculetin dibenzylether, 4- 4-Ethoxycoumarin, 7-Ethoxycoumarin, Fraxetin, Herniarin, 3-Hydroxycoumarin, 4-Hydroxycoumarin, Imperatorin, Isobergapten, Isopimpinellin, Isoscopoletin, 6-Methylcoumarin, Umberli Umbelliferone, 3-Acetyl-β-boswellic acid, α-Amyrin, β-Amyrin, Artemisinin, Betulin, Betulinic acid, Betulinic acid methyl ester Betulinic acid methyl ester, Bilobalide, Cafestol, (-)-Carveol, (+)-Carvone, (-)-Carbethyl (-)-Carvone, Caulophyllogenin, Deoxyacte Deoxyactein, Erythrodiol, Ganoderic acid A, Hederagenin, d-Isomenthol, (±)Isomenthone, Oleanolic acid, Alizarin, Alkannin, Anthraflavic acid, Anthraquinone, 1,4-Benzoquinone, 2-tert-Butyl-p- 2-Tert-butyl-p-quinone, 1,4-Dimethylanthraquinone, Emodin, Physcion, Rhein, Lyoniresinol, Urolithin, 5,7,4'-Trimethoxyflavone, Amarogentin, 6-Methylflavone, 4-Hydroxychalcone, 4'-Hydroxychalcone, Coumalic acid, Kojic acid, Parthenolide, Icariin, Ginsenoside Rb1 Rb 1), Gingerol, 10-hydroxy-2-decenoic acid, Epipinoresinol-Glc, Phillyrin, Pinoresinol, Epipinoresinol, Phillygenin, Curcumin 1, Curcumin 2 , Curcumin 3, Diasesamin, Honokiol, 5,7-Dimethoxyflavone, Sennidin A , Esculetin, Sesamol, Scopoletin, Nordihydroguaiaretic acid, Vanillic acid, trans-Cinnamic acid, Allantoin, α-Aminopropyl alcohol, α-Asarone, (±)-Synephrine, Itaconic acid, Asiatic acid, Boldine, Shikimic acid, Tyrosol, Corosolic acid, Picein, Rosmarinic acid, Isosteviol, Artepillin C, Apiole, Azulene, Marrubiin, (-)-Perillic acid, Madecassic acid acid), Mangiferin, Linalool, 2-Anisaldehyde, 3-Anisaldehyde, 4-Anisic acid, Urocanic Urocanic acid, α-(-)-Bisabolol, (-)-trans karyocyanate (-)-trans-Caryophyllene, Caryophyllene oxide, Hamamelitannin, Perillaldehyde, Bavachinin A, Betonicine, (+)-Cuparene , Nootkatone, (-)-Perillylalcohol, Pi Piperlongumine, Chamazulen, (-)-Asarinin, (-)-Sesamin, 2',4,4',6'-Tetrahydroxychalcone, Hinokitiol, Fucoxanthine, Enterodiol, Matairesinol , Podophyllotoxin, Trigonelline monohydrate, Trachelogenin, 7-Hydroxy-4'-methoxyflavone, Glycyrrhizic acid, 6-Hydroxy-4'-methoxyflavone, Dihydromyricetin, 2'-Hydroxychalcone, Zerumbone ), Apocynin, Oleacein, Crocetin, Isosorbide Dinitrate, Hydroxytyrosol, Homoprotocatechuic acid, Glutathione, Kahweol, Corilagin, Sesamolin, Ole Oleuropein, (±)-Equol, Rutin trihydrate, Vitexin, Orientin, Isovitexin, Violanthin, (+)-Taxifolin, Nari Naringin, Eudesmine, Saponarin, Limonin, Chafuroside B, Chafuroside A, Tangeretin, Sinensetin, and 3',4',5,5',6,7,8-Heptanol and 3',4',5,5',6,7,8-Heptamethoxyflavone. The compositions of the present invention may contain one or more of the above compounds.
[0016] The specific compounds mentioned above are each represented by the chemical formulas shown in the table below.
[0017] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11]
Table 1-12
Table 1-13
Table 1-14
Table 1-15
Table 1-16
Table 1-17
Table 1-18
Table 1-19
Table 1-20
Table 1-21
Table 1-22
Table 1-23
Table 1-24
Table 1-25
Table 1-26
Table 1-27
Table 1-28
Table 1-29
Table 1-30
Table 1-31
Table 1-32
Table 1-33
Table 1-34
Table 1-35
Table 1-36
Table 1-37
Table 1-38
Table 1-39
Table 1-40
Table 1-41
Table 1-42
Table 1-43
Table 1-44
Table 1-45
[0018] The above compounds may be commercially available or may be prepared by a method known to those skilled in the art. The above compounds may be prepared, for example, by appropriately performing operations such as isolation or purification from plants containing various compounds using a solvent such as water or oil. The above compounds may be in any form such as crystallized, recrystallized, or concentrated, and the form is not particularly limited.
[0019] The above compounds may be derivatized as glycosides. In this specification, the term "glycoside" refers to a compound formed by binding a hydroxyl group of a sugar to a non-saccharide compound. The sugar in the glycoside may be a monosaccharide, or a disaccharide or more than one sugar, and is not particularly limited. The type of sugar is also not particularly limited, and examples thereof include aldoses such as glucose, mannose, galactose, fucose, rhamnose, arabinose, and xylose, ketoses such as fructose, uronic acids such as glucuronic acid, galacturonic acid, and mannuronic acid, apiose, and rutinose. The sugar used in the glycoside may be a D-form, an L-form, or a mixture of D-form and L-form (DL-form), and is not particularly limited.
[0020] The composition of the present invention may contain any two or more of the above compounds. Also, the composition of the present invention may contain any three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more of the above compounds.
[0021] When multiple compounds are used, for example, biochanin A, 5-methyl-7-methoxy-iso Flavone, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, ipriflavone, butyrate , formononetin, 4'-methoxyflavone, 5,7,4'-trimethoxyflavone, 5,7-dimethoxyflavone, chrysin, 3',4'-dihydroxyflavone, 6-methoxyflavonol, diosmetin, diasesamin, luteolin, 5-methoxyflavone, apigenin, baicalein, anthraflavic acid, 6-hydroxyflavone, flavone, honokiol, ginsenoside Rb1, urocanic acid, daidzein, 4'-methoxychalcone, apiol, 4'-methoxyfuran Labanone, filigenin, matairesinol, bavakinin A, (-)-trans-caryophyllene, (±)-synephrine, mangiferin, 4-methoxychalcone, 2'-methoxyflavone, 2',4,4',6'-tetrahydroxychalcone, madecassic acid, 2,3-dimethoxy-2'-hydroxychalcone, , (-)-Perillyl alcohol, Caryophyllene oxide, α-(-)-Bisabolol, Hamame Litannin, urolithin, rhein, marubiin, 6-methoxyflavanone, nootkatone, esculetin, pinoresinol, nordihydroguaiaretic acid, gingerol, 10-hi Hydroxy-2-decenoic acid, fucoxanthin, phillyrin, α-asarone, 4'-hydroxycalciurin Con, curcumin 1, (-)-asarinin, azulene, hinokitiol, 3-anisaldehyde, dalbergin, curcumin 2, 7-hydroxyflavone, boldine, betonisin, (-)- Sesamin, picein, 6,7-dihydroxyflavone, 4-anisic acid, vanillic acid, rosmarinic acid, artemisinin, epipinoresinol glucoside, emodin, icariin, rottlerin, chrysoeriol, ellagic acid, sennidin A, linalool, 4-hydroxychalcone, 4',6,7-trihydroxyisoflavone, 3',4'-dimethoxyflavone, piperlongumine , fisetinidin chloride, hederagenin, (+)-cuparene, coumaric acid, epipinoleciol, 2-anisaldehyde, trans-cinnamic acid, artepillin C, 3-hydroxyflavone, 2',6'-dihydroxy-4,4'-dimethoxydihydrochalcone, allantoin, perilla aldehyde In particular, 4'-hydroxyflavanone, kojic acid, or 4'-hydroxyflavanone are used in combination. In addition, although not particularly limited, among the above compounds, preferred are biochanin A, 5-methyl-7-methoxy-isoflavone, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, ipriflavone, butein, formononetin, and 4'-methoxyflavone. , 5,7,4'-trimethoxyflavone, 5,7-dimethoxyflavone, chrysin, 3',4'-dihydro Xyflavone, 6-methoxyflavonol, diosmetin, diasesamin, luteolin, 5-methoxyflavone, apigenin, baicalein, anthraflavic acid, 6-hydroxyflavone Lavon, Flavone, Honokiol, Ginsenoside Rb1, Urocanic Acid, Daidzein, 4'-Methoxychalcone, Apiol, 4'-Methoxyflavanone, Filigenin, Matailesinol , bavakinin A, (-)-trans-caryophyllene, (±)-synephrine, mangiferin, 4-methyl- Toxichalcone, 2'-Methoxyflavone, 2',4,4',6'-Tetrahydroxychalcone, Madecassic Acid, 2,3-Dimethoxy-2'-Hydroxychalcone, (-)-Perillyl Alcohol, Caryophyllene Oxide, α-(-)-Bisabolol, Hamamelitannin, Urolithin, Rhein, Marubi In, 6-methoxyflavanone, nootkatone, esculetin, pinoresinol, nordihydroguaiaretic acid, gingerol, 10-hydroxy-2-decenoic acid, fucoxanthin, phillyrin, α-asarone, 4'-hydroxychalcone, curcumin 1, (-)-asarinin, azulene, hinokitiol, 3-anisaldehyde, dalbergin, or curcumin 2 may be used in combination.
[0022] In the composition of the present invention, compounds preferably used as chalcones include 2-hydroxychalcone, trans-chalcone, isoliquiritigenin, 4'-hydroxychalcone, 2',4'- Dihydroxy-4,6'-dimethoxychalcone, 4-hydroxychalcone, 4'-methoxychalcone , butein, 2,3-dimethoxy-2'-hydroxychalcone, 2',6'-dihydroxy-4,4'-dimethoxydihydrochalcone, 2',6'-dihydroxy-4,4'-dimethoxychalcone, 4-methoxychalcone, and 3,4,2',4',6'-pentahydroxychalcone.
[0023] In the composition of the present invention, the compound preferably used as the alkaloid is piperazine. They are Longmin and Mahanin.
[0024] In the composition of the present invention, compounds preferably used as anthraquinones are emodin and anthraflavic acid.
[0025] In the composition of the present invention, the compound preferably used as the isoflavan is (±)- It is equol.
[0026] In the composition of the present invention, compounds preferably used as isoflavones are 4',6,7-trihydroxyisoflavone, 5-methyl-7-methoxy-isoflavone, and ipriflavones. It is.
[0027] In the composition of the present invention, compounds that are preferably used as ellagic acid are urolithin and ellagic acid.
[0028] In the composition of the present invention, a compound preferably used as a coumarin is esculetin.
[0029] In the composition of the present invention, compounds preferably used as diarylheptanoids are curcumin 1, curcumin 2, and curcumin 3.
[0030] In the composition of the present invention, a compound preferably used as a diterpenoid is isosteviol.
[0031] In the composition of the present invention, compounds preferably used as sesquiterpenes are (-)-trans-caryophyllene and nootkatone.
[0032] In the composition of the present invention, compounds preferably used as triterpenes are hederagenin and corosolic acid.
[0033] In the composition of the present invention, a compound preferably used as a neoflavone is dalbergine.
[0034] In the composition of the present invention, compounds preferably used as phytochemicals are apocynin, 3-anisaldehyde, (+)-cuparene, and hydroxytyrosol.
[0035] In the composition of the present invention, a compound preferably used as a flavanonol is (+)-taxifolin.
[0036] In the composition of the present invention, the compound preferably used as the flavanone is 4'-methyl- These are xiflavanone, 2'-hydroxyflavanone, 3'-hydroxyflavanone, flavanone, and 6-methoxyflavanone.
[0037] In the composition of the present invention, compounds preferably used as flavonols include galangin, 3-methoxyflavone, kaempferol, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, Lavon, 3',4',5,5',6,7,8-heptamethoxyflavone, fisetin, 6-methoxyflavone These are flavonol, 7-hydroxyflavonol, and isorhamnetin.
[0038] In the composition of the present invention, compounds preferably used as flavones include violanthin, 3',4'-dihydroxyflavone, tangeretin, 2'-methoxyflavone, 7,4'-dihydro Xyloflavone, chrysoeriol, 3',4'-dimethoxyflavone, flavone, α-naphthoflavone These are lavon, diosmetin, 4'-methoxyflavone, wogonin, 6-hydroxyflavone, and 5-methoxyflavone.
[0039] In the composition of the present invention, compounds that are preferably used as lignans are eudesmin, (-)-sesamin, honokiol, sesamolin, sesamin, nordihydroguaiaretic acid, sesaminol, sesamol, episesamin, and matairesinol.
[0040] The compounds used in the composition of the present invention include 3',4'-dihydroxyflavone, 4'-methoxyflavanone, anthraflavic acid, 4'-methoxychalcone, 2'-methoxyflavones, butein, 2,3-dimethoxy-2'-hydroxychalcone, 4-methoxychalcone, 3',5,7- Trihydroxy-3,4'-dimethoxyflavone, flavone, diosmetin, 5-methyl-7-meth 4'-methoxyflavone, 6-methoxyflavonol, 6-hydroxyflavone More preferred are lavone, ipriflavone, 5-methoxyflavone, and matairesinol. By using these compounds, the effects of the present invention can be achieved at low concentrations (low contents).
[0041] Further preferred compounds for use in the composition of the present invention include 3',4'-dihydroxyflavone, 4'-methoxyflavanone, anthraflavic acid, 4'-methoxychalcone, 2'-methoxy Ciflavanone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 4-methoxychalcone, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, flavone, diosmetin, 5-methyl-7-methoxy-isoflavone, 4'-methoxyflavone, and 6-methoxyflavonol. By using these compounds, the effect of the present invention can be achieved at a low concentration (low content) and in a wide range of concentrations.
[0042] (PGC-1α) The composition of the present invention can activate PGC-1α by using the above-mentioned compound as an active ingredient. Therefore, the composition of the present invention can be used as a composition for activating PGC-1α. PGC-1α is a transcriptional coactivator, which is also called peroxisome proliferator-activated receptor gamma coactivator 1-alpha. Its functions include promoting mitochondrial biosynthesis by interacting with various transcription factors, and increasing the expression level of glucose transporter GLUT4.
[0043] PGC-1α is involved in energy metabolism in the body and is highly expressed in skeletal muscle, brown fat cells, liver, etc. Among skeletal muscles, PGC-1α is particularly highly expressed in the soleus muscle. PGC-1α mRNA for humans is located under GenBank accession no. The mouse strain is registered under GenBank accession number NM_008904. It is registered at.
[0044] In the present specification, the activation of PGC-1α means that the function of PGC-1α is enhanced. In the present specification, the activation of PGC-1α also includes the induction or promotion of the activation of PGC-1α, and also includes the phosphorylation or deacetylation of PGC-1α, the migration of PGC-1α present in the cytoplasm to the cell nucleus, the interaction of PGC-1α localized in the nucleus with other nuclear receptors or transcription factors, the inhibition of the degradation of PGC-1α protein, and the promotion of PGC-1α expression at any stage of the translation of the PGC-1α gene into PGC-1α protein.
[0045] The activity of PGC-1α is not particularly limited, but for example, as shown in the Examples below, a plasmid incorporating a cDNA in which PGC-1α and GAL4DBD are linked, and a plasmid containing a UAS base sequence and luciferase cDNA are introduced into a given cell, and co-transfected. It can be measured by examining the luciferase activity after expression. In this case, a condition to be compared is set, and if a measured value higher than that under the condition is obtained, it can be determined that PGC-1α is more activated than under the condition.
[0046] (composition) The content of the above-mentioned compound in the composition of the present invention is not particularly limited, and may be an amount that can obtain the desired effect of the present invention, taking into consideration the administration form and administration method. For example, the content of the above-mentioned compound is 0.1% by weight or more, preferably 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 5, or 10% by weight or more, based on the total weight of the composition of the present invention, and 90% by weight or less, preferably 80, 70, 60, 50, 40, 30, 20, or 15% by weight or less. As mentioned above, the composition of the present invention may contain only one of the above-mentioned compounds, or may contain two or more. When two or more compounds are contained, the content is defined as the total value of the contents of the various compounds. In addition, "% by weight" used in this specification means weight / weight (w / w) unless otherwise specified.
[0047] The composition of the present invention is characterized by containing the above-mentioned compound as an active ingredient, and PGC-1α is activated by the action of the compound. By activating PGC-1α in the body, it is possible to effectively achieve effects related to the function of PGC-1α, such as improving endurance, muscle hypertrophy, suppressing obesity, reducing stress, improving glucose metabolism function, and suppressing muscle atrophy. Therefore, the composition of the present invention can be used as a composition for improving endurance, muscle hypertrophy, suppressing obesity, reducing stress, improving glucose metabolism function, or suppressing muscle atrophy. The concept of endurance includes both muscle endurance and whole body endurance. Although not particularly limited, in the present invention, endurance preferably means muscle endurance.
[0048] The composition of the present invention can contain any additives and any ingredients that are commonly used in addition to the above-mentioned compounds depending on its form. Examples of these additives and ingredients include, but are not limited to, vitamins such as vitamin E and vitamin C, minerals, nutritional ingredients, and physiologically active ingredients such as flavorings, as well as excipients, binders, emulsifiers, tonicity agents (isotonicity agents), buffers, solubilizers, preservatives, stabilizers, antioxidants, colorants, coagulants, or coating agents that are mixed in formulations.
[0049] The composition of the present invention can be formulated into solid preparations such as tablets (including coated tablets), granules, powders, powders, or capsules, or liquid preparations such as normal liquid preparations, suspensions, or emulsions, according to known methods. These compositions can be taken as they are with water, etc. In addition, after being prepared into a form that can be easily mixed (e.g., powder form or granule form), it can be used, for example, as a raw material for pharmaceuticals.
[0050] The composition of the present invention includes, but is not limited to, a pharmaceutical composition, a food and drink composition, a food composition, a beverage composition, a cosmetic composition, etc. Non-limiting examples of food compositions include functional foods, dietary supplements, nutritional functional foods, special purpose foods, foods for specified health uses, dietary supplements, foods for dietary therapy, health foods, supplements, food additives, etc.
[0051] The composition of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes. Specifically, the composition can be used as a drug, quasi-drug, cosmetic, etc., and can also be used as a composition that explicitly or implicitly claims to improve endurance, increase muscle mass, suppress obesity, reduce stress, improve glucose metabolism, and suppress muscle atrophy, although it is not classified as such under the Pharmaceutical Affairs Law.
[0052] In another aspect, the present invention provides a method for producing a peptide having a function exhibited by activation of PGC-1α. It relates to a composition. Such indications or functional indications are not particularly limited, but examples thereof include "improve endurance", "support endurance", "maintain endurance", "build endurance", "help to increase stamina", "make the body less prone to fatigue", "reduce fatigue", "suppress fatigue", "accelerate fatigue recovery", "build muscle", "increase muscle", "build muscle", "reduce fat", "burn fat", "suppress obesity", "prevent obesity", "enhance lipid metabolism", "reduce stress", "enhance stress resistance", "suppress depression", "prevent depression", "promote glucose metabolism", "enhance glucose metabolism", "promote sugar burning", "support glucose metabolism", "consume sugar", "maintain muscle", "suppress muscle atrophy", "prevent muscle loss", "suppress muscle loss", "prevent muscle atrophy", "suppress muscle atrophy", and other indications or functional indications that can be regarded as equivalent thereto. In the present specification, such indications and functional indications may be attached to the composition itself, or to the container or packaging of the composition.
[0053] The composition of the present invention can be ingested in a suitable manner according to its form.The composition of the present invention can be in the form of, for example, a solid oral preparation, an oral liquid preparation such as an oral liquid preparation or a syrup, or a parenteral preparation such as an injection, an external preparation, a suppository, or a transdermal absorption agent, but is not limited thereto.In addition, in this specification, the term "ingestion" is used to include all aspects such as ingestion, taking, or drinking.
[0054] The dosage of the composition of the present invention is determined according to its form, administration method, purpose of use, and age, weight, and symptoms of the patient or animal to which it is administered, and is not fixed. The effective human intake of the composition of the present invention is not fixed, but for example, the weight of the above compound, which is its active ingredient, is preferably 100 mg or more, more preferably 500 mg or more, and even more preferably 1000 mg or more, and preferably 10 g or less, more preferably 5 g or less, and even more preferably 3 g or less per day for a human weighing 50 kg. In addition, the administration may be performed once or several times within a day within the desired dosage range. The administration period is also arbitrary. The effective human intake of the composition of the present invention refers to the intake amount of the composition of the present invention that shows an effective effect in humans, and the type of compound contained in the composition is not particularly limited.
[0055] The subject of application of the composition of the present invention is preferably humans, but may also be livestock animals such as cows, horses, goats, etc., pet animals such as dogs, cats, rabbits, etc., or experimental animals such as mice, rats, guinea pigs, monkeys, etc. When administered to animals other than humans, the daily usage amount for about 20 g per rat varies depending on the content of the active ingredient in the composition, the condition, weight, sex, age, etc. of the subject, but for example, the total amount of the above compounds is preferably 10 mg / kg or more, more preferably 50 mg / kg or more, even more preferably 100 mg / kg or more, and preferably 1 g / kg or less, more preferably 500 mg / kg or less, even more preferably 300 mg / kg or less.
[0056] (Use for activating PGC-1α) One aspect of the present invention is the use of at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans to activate PGC-1α.
[0057] In the present invention, the specific compounds described above can be used. In the present invention, the chalcones include 2-hydroxychalcone, trans-chalcone, isoliquiritigenin, 4'-hydroxychalcone, 2',4'-dihydroxy-4,6'-dimethoxychalcone, 4-hydroxychalcone, 4-hydroxy-4,6'-dimethoxy ... 4'-Methoxychalcone, butein, 2,3-dimethoxy-2'-hydroxychalcone Chalcone, 2',6'-dihydroxy-4,4'-dimethoxydihydrochalcone, 2',6'-dihydroxy-4 ,4'-Dimethoxychalcone, 4-Methoxychalcone, and 3,4,2',4',6'-Pentahydroxychalcone Lucon is preferred.
[0058] In the present invention, the preferred alkaloids are piperlongumine and mahanine.
[0059] In the present invention, the preferred anthraquinones are emodin and anthraflavic acid.
[0060] In the present invention, the isoflavan is preferably (±)-equol.
[0061] In the present invention, the isoflavones include 4',6,7-trihydroxyisoflavones. Of these, 5-methyl-7-methoxy-isoflavone, and ipriflavone are preferred.
[0062] In the use of the present invention, urolithin and ellagic acid are preferred as ellagic acid.
[0063] In the present invention, the coumarin is preferably esculetin.
[0064] In the present invention, the diarylheptanoids curcumin 1, curcumin 2, and curcumin 3 are preferred.
[0065] In the present invention, the diterpenoid is preferably isosteviol.
[0066] In the present invention, the sesquiterpenes include (-)-trans caryophyllene and Tokatone is preferred.
[0067] In the present invention, the preferred triterpenes are hederagenin and corosolic acid.
[0068] In the present invention, the neoflavones are preferably dalbergines.
[0069] For use in the present invention, the phytochemicals preferred are apocynin, 3-anisaldehyde, (+)-cuparene, and hydroxytyrosol.
[0070] In the present invention, the flavanonol is preferably (+)-taxifolin.
[0071] In the present invention, preferred flavanones are 4'-methoxyflavanone, 2'-hydroxyflavanone, 3'-hydroxyflavanone, flavanone, and 6-methoxyflavanone. I wish.
[0072] In the present invention, preferred flavonols are galangin, 3-methoxyflavone, kaempferol, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, 3',4',5,5',6,7,8-heptamethoxyflavone, fisetin, 6-methoxyflavonol, 7-hydroxyflavonol, and isorhamnetin.
[0073] In the present invention, preferred flavones include biolanthin, 3',4'-dihydroxyflavone, tangeretin, 2'-methoxyflavone, 7,4'-dihydroxyflavone, chrysoeriol, 3',4'-dimethoxyflavone, flavone, α-naphthoflavone, diosmetin, 4'-methoxyflavone, wogonin, 6-hydroxyflavone, and 5-methoxyflavone. It is.
[0074] In the present invention, preferred lignans are eudesmin, (-)-sesamin, honokiol, sesamolin, sesamin, nordihydroguaiaretic acid, sesaminol, sesamol, episesamin, and matairesinol.
[0075] The compounds used in the present invention include 3',4'-dihydroxyflavone, 4'-methoxyflavone, Ciflavanone, anthraflavic acid, 4'-methoxychalcone, 2'-methoxyflavone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 4-methoxychalcone, 3',5,7-trihydro More preferred are 3,4'-dimethoxyflavone, flavone, diosmetin, 5-methyl-7-methoxy-isoflavone, 4'-methoxyflavone, 6-methoxyflavonol, 6-hydroxyflavone, ipriflavone, 5-methoxyflavone, and matairesinol. By using these compounds, the effect of the present invention can be achieved at a low concentration (low content).
[0076] Further, more preferred compounds for use in the present invention include 3',4'-dihydroxyflavone, 4'-methoxyflavanone, anthraflavic acid, 4'-methoxychalcone, 2'-methyl-2-propanediol ... Toxiflavone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 4-methoxychalcone, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, flavone, diosmetin, 5-methyl 4'-methoxyflavone, 6-methoxyflavone, and 7-methoxy-isoflavone By using these compounds, the effects of the present invention can be exhibited at low concentrations (low contents) and over a wide concentration range.
[0077] The use of the present invention includes, but is not limited to, the use of the above-mentioned compound for, for example, improving endurance, muscle hypertrophy, suppressing obesity, reducing stress, improving glucose metabolism function, or suppressing muscle atrophy. The use may be in humans or non-human animals, and may be therapeutic or non-therapeutic. Here, "non-therapeutic" is a concept that does not include medical procedures, i.e., treatment of the human body by treatment.
[0078] (Methods for activating PGC-1α) One aspect of the present invention is a method for activating PGC-1α, using at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans. Another aspect of the method is a method for activating PGC-1α, comprising administering a therapeutically effective amount of the compound as an active ingredient to a subject in need of PGC-1α activation.
[0079] In the method of the present invention, the specific compounds described above can be used. In the method of the present invention, the compounds preferably used as chalcones are 2-hydroxychalcone, trans-chalcone, isoliquiritigenin, 4'-hydroxychalcone, 2',4'-dihydroxy-4,6'-dimethoxychalcone, 4-hydroxychalcone, 4'-methoxychalcone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 2',6'-dihydroxy-4,4'-dimethoxydihydrochalcone, 2',6'-dihydroxy-4,4'-dimethoxychalcone, 4-methoxychalcone, and 3,4,2',4',6'-pentahydroxychalcone.
[0080] In the method of the present invention, compounds preferably used as alkaloids are piperlongumine and mahanine.
[0081] In the method of the present invention, compounds preferably used as anthraquinones are emodin and anthraflavic acid.
[0082] In the method of the present invention, the compound preferably used as the isoflavan is (±)- It's quarl.
[0083] In the method of the present invention, the compound preferably used as the isoflavone is 4',6,7- Trihydroxyisoflavone, 5-methyl-7-methoxy-isoflavone, and ipriflavone.
[0084] In the method of the present invention, compounds preferably used as ellagic acid are urolithin and ellagic acid.
[0085] In the method of the present invention, a compound preferably used as a coumarin is esculetin.
[0086] In the method of the present invention, compounds preferably used as diarylheptanoids are curcumin 1, curcumin 2, and curcumin 3.
[0087] In the method of the present invention, a compound preferably used as a diterpenoid is isosteviol.
[0088] In the method of the present invention, compounds preferably used as sesquiterpenes are (-)-trans-caryophyllene and nootkatone.
[0089] In the method of the present invention, compounds preferably used as triterpenes are hederagenin and corosolic acid.
[0090] In the method of the present invention, a compound preferably used as a neoflavones is dalbergine.
[0091] In the method of the present invention, compounds preferably used as phytochemicals are apocynin, 3-anisaldehyde, (+)-cuparene, and hydroxytyrosol.
[0092] In the method of the present invention, a compound preferably used as a flavanonol is (+)-taxifolin.
[0093] In the method of the present invention, the compound preferably used as the flavanone is 4'-methoxy- They are cycloflavanone, 2'-hydroxyflavanone, 3'-hydroxyflavanone, flavanone, and 6-methoxyflavanone.
[0094] In the method of the present invention, compounds preferably used as flavonols include galangin, 3-methoxyflavone, kaempferol, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, Fisetin, 3',4',5,5',6,7,8-heptamethoxyflavone, fisetin, 6-methoxyflavone These are flavonol, 7-hydroxyflavonol, and isorhamnetin.
[0095] In the method of the present invention, compounds preferably used as flavones include violanthin, 3',4'-dihydroxyflavone, tangeretin, 2'-methoxyflavone, 7,4'-dihydroxyflavone, chrysoeriol, 3',4'-dimethoxyflavone, flavone, α-naphthofuranoside, and α-naphthofuranoside. These are wogonin, diosmetin, 4'-methoxyflavone, wogonin, 6-hydroxyflavone, and 5-methoxyflavone.
[0096] In the method of the present invention, compounds that are preferably used as lignans are eudesmin, (-)-sesamin, honokiol, sesamolin, sesamin, nordihydroguaiaretic acid, sesaminol, sesamol, episesamin, and matairesinol.
[0097] The compounds used in the method of the present invention include 3',4'-dihydroxyflavone, 4'- Methoxyflavanone, anthraflavic acid, 4'-methoxychalcone, 2'-methoxyflavone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 4-methoxychalcone, 3',5,7-trimethoxy Trihydroxy-3,4'-dimethoxyflavone, flavone, diosmetin, 5-methyl-7-methoxy C-isoflavone, 4'-methoxyflavone, 6-methoxyflavonol, 6-hydroxyflavonol More preferred are 5-methoxyflavone, ipriflavone, 5-methoxyflavone, and matairesinol. If these compounds are used, the effects of the present invention can be achieved at a low concentration (low content).
[0098] Further preferred compounds for use in the method of the present invention include 3',4'-dihydroxyflavone, 4'-methoxyflavanone, anthraflavic acid, 4'-methoxychalcone, 2'-methoxy Flavone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 4-methoxychalcone, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, flavone, diosmetin, 5-methyl-7-methoxy-isoflavone, 4'-methoxyflavone, and 6-methoxyflavonol. By using these compounds, the effect of the present invention can be achieved at a low concentration (low content) and in a wide range of concentrations.
[0099] In the above method, the subject who needs to activate PGC-1α is the same as the subject to which the composition of the present invention is applied.In addition, in this specification, the therapeutically effective amount refers to the amount of PGC-1α that is activated when the composition of the present invention is administered to the subject, compared to a subject not administered the composition.The specific effective amount is not fixed and is set appropriately depending on the administration form, administration method, purpose of use, and age, weight, symptoms, etc. of the subject.
[0100] In the method of the present invention, the above-mentioned compound may be administered as it is or as a composition containing the above-mentioned compound so as to achieve the above-mentioned therapeutically effective amount.
[0101] According to the method of the present invention, it is possible to activate PGC-1α without causing side effects. EXAMPLES
[0102] The present invention will be described in more detail below with reference to examples, but the scope of the present invention is not limited thereto. Those skilled in the art can use the method of the present invention by variously changing and modifying it, and these are also included in the scope of the present invention. All of the following examples were carried out at Shizuoka Prefectural University.
[0103] Commercially available human fetal kidney-derived HEK293T cells were placed in a 60 mm dish in D-MEM (containing 10% FBS and antibiotics (penicillin, streptomycin, and amphotericin B) medium and incubated with CO. 2 Incubator at 37°C and 5% CO 2The cells were subcultured under conditions of +95% air and 100% humidity. After confirming that the cell density was 70-90% confluent, the HEK293T cells were washed with PBS, then treated with trypsin solution (0.05% (w / v) trypsin, 0.53 mM EDTA·4Na), and the detached cells were collected by centrifugation at 1,200 rpm. The collected cells were resuspended in D-MEM (containing 10% FBS), the cell number was counted, and they were used for subculture and testing.
[0104] A cDNA in which yeast-derived GAL4DBD (GAL4-DNA Binding Domain) and mouse-derived PGC-1α were combined was inserted into an expression plasmid to prepare a PGC-1α plasmid. This PGC-1α plasmid and a plasmid containing a UAS base sequence, and an internal control plasmid containing the luciferase gene were introduced into HEK293T cells.
[0105] After gene transfer, HEK293T cells were incubated in CO 2 Incubator at 37°C and 5% CO 2 The cells were cultured for 24 hours under conditions of +95% air and 100% humidity, after which the test substance dissolved in water or DMSO was added to a final concentration of 1 μg / mL or 10 μg / mL.
[0106] Luciferase (Luc) activity was measured 24 hours after the addition of the test substance, and the measured value was divided by the measured value of the internal standard Luc activity to obtain the PGC-1α activity. In order to evaluate the PGC-1α activity of the test substance, the PGC-1α activity when water or DMSO was used as the test substance was set as 100%, and the PGC-1α activity of all test substances was shown as a relative percentage. The results are shown in the table below.
[0107] [Table 2]
[0108] [Table 3-1] [Table 3-2]
[0109] As mentioned above, all compounds with a measured value (relative ratio) of more than 200% at a final concentration of 1 μg / mL or 10 μg / mL were shown to have the ability to activate PGC-1α. '-Methoxychalcone, 2'-methoxyflavone, butein, 2,3-dimethoxy-2'-hydroxy Chalcone, 4-methoxychalcone, 3',5,7-trihydroxy-3,4'-dimethoxyflavone, Lavon, diosmetin, 5-methyl-7-methoxy-isoflavone, 4'-methoxyflavone, and For 6-methoxyflavonol and 6-methoxyflavonol, the measured values exceeded 200% at both the final concentrations of 1 μg / mL and 10 μg / mL. In addition to the above, 31 other compounds were tested and confirmed to have no PGC-1α activation ability. [Industrial Applicability]
[0110] The present invention provides a composition containing a specific compound as an active ingredient and useful for activating PGC-1α. The present invention provides a new means for improving endurance, increasing muscle hypertrophy, suppressing obesity, reducing stress, improving glucose metabolism, and suppressing muscle atrophy, and is therefore highly industrially applicable.
Claims
1. A composition for activating PGC-1α, comprising at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans.
2. The chalcones are 2-hydroxychalcone, trans-chalcone, isoliquiritigenin, 4'- Hydroxychalcone, 2',4'-dihydroxy-4,6'-dimethoxychalcone, 4-hydroxychalcone, 4'-methoxychalcone, butein, 2,3-dimethoxy-2'-hydroxychalcone, 2',6'-dihydroxy-4,4'-dimethoxydihydrochalcone, 2',6'-dihydroxy-4,4'-dimethoxy Consists of cyclochalcone, 4-methoxychalcone, and 3,4,2',4',6'-pentahydroxychalcone. The composition of claim 1, wherein the compound is at least one compound selected from the group consisting of:
3. 3. The composition according to claim 1 or 2, wherein the alkaloids are piperlongumine and / or mahanine.
4. The composition according to any one of claims 1 to 3, wherein the anthraquinones are emodin and / or anthraflavic acid.
5. The composition according to any one of claims 1 to 4, wherein the isoflavan is (±)-equol. Composition.
6. Isoflavones are 4',6,7-trihydroxyisoflavone, 5-methyl-7-methoxy-iso The composition according to any one of claims 1 to 5, which is at least one compound selected from the group consisting of flavone and ipriflavone.
7. The composition according to any one of claims 1 to 6, wherein the ellagic acid is urolithin and / or ellagic acid.
8. The composition according to any one of claims 1 to 7, wherein the coumarin is esculetin.
9. The composition according to any one of claims 1 to 8, wherein the diarylheptanoid is at least one compound selected from the group consisting of curcumin 1, curcumin 2, and curcumin 3.
10. The composition according to any one of claims 1 to 9, wherein the diterpenoid is isosteviol.
11. The sesquiterpenes are (-)-trans caryophyllene and / or nootkatone. Item 11. The composition according to any one of items 1 to 10.
12. The composition according to any one of claims 1 to 11, wherein the triterpenes are hederagenin and / or corosolic acid.
13. The composition according to any one of claims 1 to 12, wherein the neoflavones are dalbergines.
14. The phytochemicals are apocynin, 3-anisaldehyde, (+)-cuparene, and hydroxyl. The composition according to any one of claims 1 to 13, which is at least one compound selected from the group consisting of citrosol.
15. The composition according to any one of claims 1 to 14, wherein the flavanonol is (+)-taxifolin.
16. Flavanones are 4'-methoxyflavanone, 2'-hydroxyflavanone, and 3'-hydroxy The composition according to any one of claims 1 to 15, which is at least one compound selected from the group consisting of flavanone, flavanone, and 6-methoxyflavanone.
17. Flavonols include galangin, 3-methoxyflavone, kaempferol, and 3',5,7-trimethylol. 3,4'-hydroxy-dimethoxyflavone, 3',4',5,5',6,7,8-heptamethoxyflavone, The composition according to any one of claims 1 to 16, which is at least one compound selected from the group consisting of cetin, 6-methoxyflavonol, 7-hydroxyflavonol, and isorhamnetin.
18. Flavones include biolanthin, 3',4'-dihydroxyflavone, tangeretin, and 2'-methionine. Xyloflavone, 7,4'-dihydroxyflavone, chrysoeriol, 3',4'-dimethoxyflavone At least one selected from the group consisting of flavone, flavone, α-naphthoflavone, diosmetin, 4'-methoxyflavone, wogonin, 6-hydroxyflavone, and 5-methoxyflavone. The composition according to any one of claims 1 to 17, wherein the compound is a compound selected from the group consisting of phenyl, ...
19. The composition according to any one of claims 1 to 18, wherein the lignans are at least one compound selected from the group consisting of eudesmin, (-)-sesamin, honokiol, sesamolin, sesamin, nordihydroguaiaretic acid, sesaminol, sesamol, episesamin, and matairesinol.
20. The composition according to any one of claims 1 to 19, which is for improving endurance, for increasing muscle hypertrophy, for suppressing obesity, for reducing stress, for improving glucose metabolic function, or for suppressing muscle atrophy.
21. The composition according to any one of claims 1 to 20, which is indicated as having a function exerted by activation of PGC-1α.
22. 22. The composition of claim 21, wherein the functional indication is selected from the group consisting of "enhance endurance," "support endurance," "maintain endurance," "build endurance," "help to increase stamina," "make the body less prone to fatigue," "reduce fatigue," "suppress fatigue," "speed up recovery from fatigue," "build muscle," "increase muscle," "build muscle," "reduce fat," "burn fat," "suppress obesity," "prevent obesity," "enhance lipid metabolism," "reduce stress," "enhance stress tolerance," "suppress depression," "prevent depression," "promote glucose metabolism," "enhance glucose metabolism," "promote sugar burning," "support glucose metabolism," "consume sugar," "maintain muscle," "inhibit muscle atrophy," "prevent muscle loss," "inhibit muscle loss," "prevent muscle decline," and "inhibit muscle decline."
23. Use of at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans, for activating PGC-1α.
24. A method for activating PGC-1α using at least one compound selected from the group consisting of chalcones, alkaloids, anthraquinones, isoflavans, isoflavones, ellagic acid, coumarins, diarylheptanoids, diterpenoids, sesquiterpenes, triterpenes, neoflavones, phytochemicals, flavanonols, flavanones, flavonols, flavones, and lignans.
Citation Information
Patent Citations
Pet food
JP2013126411A
Pet food
WO2014098193A1
US200910620405-20410
